Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

A Multi-enter, Randomized, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (10, 15, and 20 mcg) of GSK159797

This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.

Inclusion criteria:

• Subjects with documented history of persistent asthma using corticosteroids at a total daily dose of 200 to 200mcg of FP or equivalent corticosteroid
• Female subjects only using acceptable birth control method
• Non-smokers
• FEV1 between 60 and 90% predicted
• Increase in FEV1 12% or greater and 300mL and greater after salbutamol use

Exclusion criteria:

• Past or present disease conditions
• Normal screening Holter ECG
• Respiratory tract infection within 4 weeks of screening
• History of life threatening asthma
• Previous use of COA